ArticleThe oncologist2020

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.

Robert Wesolowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.